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 Introduction: The clinical usage of the ureteral stent 
caused several stent-related symptoms (SRSs), including 
lower urinary tract symptoms, pain, general health, work 
performance, sexual matter and additional problems. This 
study aims to evaluate the effectiveness between 
tamsulosin and solifenacin combined with tamsulosin for 
SRSs. 
Methods: This double blind randomized controlled trial 
used 50 patients. Between September 2020 and February 
2021, patients underwent double-J stenting after 
retrograde ureteroscopy were analyzed. All patients would 
be randomized in a 1:1 ratio in a 1:1 ratio to receive either 
tamsulosin 0,4 mg (Group A: 25 participants) or 
tamsulosin 0,4 mg & solifenacin 5 mg combination (group 
B: 25 participants).We used the Ureteral Symptoms Score 
Questionnaire (USSQ) as an outcome measure at 1s, 2nd, 
3rd and 4th weeks after stent insertion. Results: Group A 
was found more in women, while in group B was more in 
men. The highest age in group A and group B was 50-60 
years old (36% and 64%). The location of stenting in group 
A was found more in left (60%), while the group B in the 











  Ureteral stent placement is very common procedure performed in urologic 
practice. With the widespread use of indwelling ureteral stents by urologist for urinary 
diversion, ureteral obstruction relief, and postoperative drainage, issues related to their 
use have also increased.1 Despite  the wide clinical usage of the ureteral stent, it causes 
various stent-related symptoms (SRSs), including lower urinary tract symptoms (LUTS), 
hematuria, body pain, and sexual problems, and ultimately deteriorates the quality of life 
(QoL) of patients.2 Up to 80% of patients report on a reduced QoL as a result of the 
symptoms arising from ureteral stents and the procedure is associated with considerable 
economic burden.3  
  To reduce the incidence of SRSs, initial efforts have been made to optimize the 
physical properties of ureteral stents, such as the material, length, design and position. 
However, as the stent size and designs to reduce SRSs seem limited, optimal stent is 
still yet to be developed. Nevertheless, oral pharmacologic treatment, has shown 
beneficial effects of which alpha-blockers and antimuscarinics were mostly adopted.4 
Tamsulosin acts mainly on the urethra, bladder neck and prostate and has a selective 
blocking effect on smooth muscle in these organs. Tamsolusin can improve LUTS and 
prevent as well as treat the urinary retention. In addition, tamsulosin can also be used 
for urinary calculi and adjuvant treatment of male sexual dysfunction. Solifenacin, a 
muscarinic acetylcholine M3 receptor blocker (M3-blocker), is an anticholinergic drug 
with high selectivity. It has been suggested that M3 receptors on the bladder detrusor 
muscle might be the target of this drug. Through inhibiting and blocking the binding of 
acetylcholine to the M3 receptor, reducing the contractile force of the detrusor, and 
inhibiting contraction of the detrusor, solifenacin can improve the symptoms of frequent 
urination and urgency. 5 Solifenacin is the first-line therapy for overactive bladder (OAB) 
symptoms in LUTS. For all these reasons, antimuscarinics combined with alpha-blockers 
were recommended for storage symptoms of LUTS.6 
  Lim Kyoung et al reported that combination therapy with tamsulosin and 
solifenacin improved obstructive and irritative symptoms and quality of life more than in 
the control group. Therefore, combination therapy with tamsulosin dan solifenacin should 
be strongly considered for patients who complain of SRSs.7 Yan et al also reported that 
the combined  use of antimuscarinics and alpha-blockers results in addictive favorable 
effects in patients with ureteral stent-related symptoms compared with antimuscarinics 
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normal nutritional status (60%). There was an 
improvement in pain and work performance after 
treatment in both groups, meanwhile group B showed 
better improvement than group A at all weeks. in addition, 
there was an improvement in urinary symptoms and 
sexual matter in group B better than in group A at 2nd to 4th 
week. Furthermore, group B showed better improvement 
in general health and additional problem only at 4th week. 
Conclusions: Combination therapy with tamsulosin and 
solifenacin improved USSQ score more than the 
monotherapy group. This implied that combination therapy 
is optimal for improving SRSs. 
 Copyright © 2021 NMSJ. All rights reserved. 





monotherapy. The alpha-blockers may enhace the efficacy of the antimuscarinics, which 
is beneficial for the treatment of SRSs.8 In the last few decades, many studies have 
researched effectiveness regarding alpha-blocker and antimuscarinic combined therapy 
compared with alpha-blocker monotherapy. However, the research included different 
kinds of alpha-blockers and antimuscarinic, and their results are not completely 
consistent.6 Through our research, we aimed to evaluate the effectiveness of tamsulosin 
and solifenacin combined therapy with tamsulosin monotherapy for SRSs. 
 
2. METHODS 
  This was a double blind, randomized controlled trial (RCT). According to sample 
size calculation, 50 patients between September 2020 and February 2021 underwent 
double-J stenting retrogradely after retrograde ureteroscopy were analyzed. Both male 
and female, age 20-60 years old, first inserting and unilateral stenting were included in 
this study. Patients who were diagnosed with hypertension, diabetes mellitus, 
malignancy, pregnancy and urinary tract infection were excluded from this study.  
 All participants would be randomized in a 1:1 ratio to receive either tamsulosin 0,4 
mg (group A; 25 participants) or tamsulosin 0,4 mg & solifenacin 5 mg combination 
(group B: 25 participants). We used the Ureteral Symptoms Score Questionnaire 
(USSQ) to all participants as outcome measure at 1, 2, 3 and 4 weeks after stent 
inserting. 
  We hypothesized that medication therapy using tamsulosin and solifenacin 
combination might be superior to tamsulosin as monotherapy. The Independent T-test, 
repeated ANOVA test, and Friedman test were used for compassion between groups. 
All statistical analyses were performed using SPSS version 17.0 with p<0.05 indicating 
satirically significant differences.  
 
3. RESULTS 
  Group A (tamsulosin) had more women (52%) that Group B (tamsulosin and 
solifenacin combined therapy) conversely Group B had more men (56%) than Group A. 
The highest age of Group A and Group B was 50-60 years old (36% and 64%). The 
location of stenting in group A was found more in left (60%) while the group B in the right 
(52%). Both groups had more patients who were normal nutritional status (60%) (Table 
1). 
 
Table 1. The Characteristics of Patients. 
 Group A Group B 
Number % Number % 
Sex 
Male 12 48 14 56 
Female 13 52 11 44 
 
Ages (years old) 
 20-29  2 8 2 8 
 30-39  6 24 1 4 
 40-49  8 32 6 24 
 50-60  9 36 16 64 
 
Stenting 
 Right  10 40 13 52 




 Left  15 60 12 48 
 
Nutritional Status 
  Normal  15 60 15 60 
 Obesity  10 40 10 40 
   
  There was improvement of urinary symptoms after treatment in both groups, 
meanwhile group B showed better improvement than group A at 2nd to 4th week. Also, 
there was improvement of pain after treatment in both groups, meanwhile group B 
showed better improvement than group A at 1st to 4th week.  
 
Table 2. Summary of Ureteral Stent Symptom Score 
Week Group Mean ± SD p-valuea p-valueb p-valuec 
Urinary Symptoms   
1ST  
A 20.60 ± 4.6 
0.40 
0.001* 0.001# 
B 21.48 ± 2.3 
2nd  
A 14.32 ± 4.9 
0.001 
B 6.56 ± 2.4 
3rd 
A 11.56 ± 4.2 
0.001 
B 3.20 ± 1.2 
4th 
A 8.92 ± 4.8 
0.001 




1ST  A 15.36 ± 4.1 0.001 
0.001* 0.001# 
 B 19.16 ± 2.3  
2nd  A 10.76 ± 4.0 0.001 
 B 6.80 ± 1.6  
3rd A 8.36 ± 3.4  0.001 
 B 2.04 ± 1.1  
4th A 5.44 ± 3.9 0.001 
 B 1.32 ± 0.9  
      
General Health   
1ST  A 6.24 ± 2.5 0.07 
0.001* 0.001# 
 B 7.28 ± 1.4  
2nd  A 4.24 ± 2.4 0.85 
 B 4.12 ± 2.3  
3rd A 3.04 ± 2.4 0.12 
 B 2.20 ± 1.0  
4th A 2.12 ± 2.2 0.001 
 B 0.72 ± 0.9  
      
Work Performance   
1ST  A 6.40 ± 3.2 0.001 
0.001* 0.001# 
 B 6.64 ± 0.9  
2nd  A 4.96 ± 3.2 0.001 
 B 2.76 ± 0.6  
3rd A 3.36 ± 2.8 0.001 
 B 1.68 ± 1.7  
4th A 2.52 ± 0.5 0.001 
 B 0.20 ± 0.5  
      
Sexual Matter   
1ST  A 0.72 ± 1.5 0.60 
0.26* 0.001# 
 B 1.32 ± 1.4  
2nd  A 0.72 ± 1.2 0.03 
 B 0.40 ± 0.7  
3rd A 0.52 ± 0.9 0.001 
 B 0.00 ± 0.0  





4th A 0.44 ± 0.8 0.001 
 B 0.00 ± 0.0  
      
Additional 
Problems 
     
1ST  A 7.04 ± 1.3 0.10 
0.001* 0.001# 
 B 5.52 ± 1.6  
2nd  A 4.32 ± 1.5 0.73 
 B 3.88 ± 1.7  
3rd A 3.84 ± 1.1 0.90 
 B 1.48 ± 0.9  
4th A 3.56 ± 1.4 0.02 
 B 0.44 ± 0.6  
a Comparation between Group A & B using Independent T-test, bcomparation between week & Group A, 
comparation between week & Group B*, c Repeated ANOVA test, and Friedman test#. 
   
  About general health, there was improvement after treatment in both groups and 
group B showed better improvement than group A only at 4th week. However, there was 
improvement of work performance after treatment in both groups and group B showed 
better improvement than group A from 1st to 4th week. Sexual matter improvement after 
treatment showed better improvement in group B from 2nd  to 4th week. Additional 
problem improvement after treatment showed better improvement in group B from only 
in the 4th week. Overall, There was an improvement of USSQ scores from 1st to 4th weeks 
in both group except sexual matter in group A (table 2).  
 
Table 3. Summary of Independent variables for USSQ 
Week USSQ Variabel Mean  
Standardized 
coefficients (p-value) 
1st   Pain Treatment  Group A (15.36 ± 4.19) 





Treatment Group A (7.04 ±  0.26) 
Group B (5.52 ±  1.64) 
 
-0.422 (0.003) 
2nd  Urinary 
Symptoms 
Treatment Group A(14.32 ± 4.95) 
Group B (6.56 ± 2.43) 
 
-0.700 (0.001) 
 Pain Treatment Group A (10.76 ± 4.07) 





Treatment Group A (5.17 ± 3.17) 
Group B (2.76 ± 0.13) 
 
-0.432 (0.004) 
3rd  Urinary 
Symptoms  
Treatment Group A (3.04 ± 0.48) 
Group B (3.20 ± 1.22) 
 
-0.774 (0.001) 




Group A (8.36 ± 3.50) 
Group B (2.04 ± 0.23) 
 
Right stent (6.00 ± 4.66) 













Group A (0.91 ± 0.37) 
Group B (0.00 ± 0.00) 
 
Male (0.42 ± 0.95) 
Female (0.08 ± 0.28) 
 
Normal (0.38 ± 0.18) 















Treatment Group A (3.84 ±  0.22) 
Group B (1.48 ±  0.17) 
 
-0.788 (0.001) 






Group A (8.92 ± 4.83) 
Group B (2.52 ± 1.12) 
 
Right Stent (6.81 ± 5.95 ) 






 Pain Treatment Group A (5.44 ± 3.93) 
Group B (1.32 ± 0.20) 
 
-0.564 (0.001) 




Group A (2.12 ± 0.45) 
Group B (0.72 ± 0.20) 
 
Right Stent (1.96 ± 2.12) 








Treatment Group A (2.62 ± 0.62) 
Group B (0.20 ± 0.10) 
 
-0.443 (0.001) 







Group A (0.73 ± 0.27) 
Group B (0.00 ± 0.00) 
 
Male  (0.35 ± 0.74) 
Female (0.08 ± 0.28) 
 
Normal (0.31 ± 0.14) 











Treatment Group A (3.56 ±  0.29) 
Group B (0.44 ±  0.17) 
-0.825 (0.001) 
Comparation between Group A & B using Independent T-test 
 
  Significant differences were found more frequently at the last week (3rd-4th week) 
than at the beginning of the week (1st-2nd week) for all variables including gender, age, 
stenting, and nutritional status (appendix 1-4). For all the existing variables, drug 
administration, which was the main independent variable in this study, had the greatest 
influence on all domains at all weeks compared to other significant variables (table 3).  
 
4. DISCUSSIONS 
  Despite of growing number of studies on SRSs, explicit pathophysiology is still 
matter of debate. SRSs may be the result of ureteric spasm or trigonal irritation. Pain 
and lower urinary tract symptoms caused be worsened by the increasing pressure 
transmitted to the renal pelvis during urination, bladder ischemia and lower ureteric 
bladder spasm. SRSs may also exacerbate pre-existing subclinical detrusor over-activity 
and induce overactive bladder symptoms.9 
  Our study revealed that tamsulosin & solifenacin combination (group B)  was 
significantly effective for SRSs with comparable results in tamsulosin group (group A) 
based on USSQ score, which is regarded as the best questionnaire for assessing SRS 
at present. Jian Zhongyu et al demonstrated that combination of tamsulosin and 
solifenacin had highest probability to the best intervention for SRSs. This combination 
might had a synergistic effect, owing to simultaneous inhibition of receptors on smooth 
muscle located in bladder neck region, lower segment of ureter and detrusor. Alpha-
blockers had been proved able to inhibit ureteral contractility in decreased peak ureteral 





contraction pressures, which may prevent continuously contracted state of the ureteral 
smooth muscle caused by the indwelling stent, resulting in ureter dilatation and 
improvement in drainage. Therefore, alpha-blockers, by reducing muscle spasm and 
vesicoureteric reflux, can effectively release body pain. With inhibitive effect on 
Muscarinic-receptors of detrusor smooth muscle cell, solifenacin may be able to handle 
these symptoms more effectively. Solifenacin had the ability to inhibit abnormal activity 
of bladder smooth muscle and decreased local contractions of the detrusor.10 
  Regarding USSQ, combination therapy improved urinary symptoms, pain, work 
performance and sexual matter in almost all weeks. But, general health and additional 
problem were only improved in 4th week. Yan et al analyzed that alpha-blocker plus 
antimuscarinics are superior to monotherapy for treatment ureteral stend-related 
symptoms. Six studies including 483 patients compared the combination therapy of 
alpha-blockers and antimuscarinics with monotherapy in the treatment of SRSs. 
Combination therapy improved the pain and work performances score.8 
  There was no reported of side effects both combination and monotherapy in this 
study. Lim Kyoung et al reported, the side effects of combination therapy were minimal. 
No patients discontinued the medication because of side effects.7 Dellis Athanasios et al 
also showed no patients had to discontinue combination therapy because of side effects 
or underwent stent removal before the due date.11 
  There are several limitations in our study, although our study was conducted 
strictly following the methodology of evidence-based medicine. Firstly, number of 
samples is limited due to COVID-19 pandemic. Secondly, different surgical treatments 
would also lead to heterogeneity. For example, patients receiving ESWL or ureteroscopic 




  Combination therapy with tamsulosin and solifenacin improved USSQ score 
more than in monotherapy group. It is implied that combination therapy is optimal to 
improve SRSs. However, further large-scale & prospective study are needed to get more 
accurate information.  
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1st week 2nd week 3rd week  4th week 
Group 
A  
Group B p-value Group 
A  
Group B p-value Group 
A  
Group B p-value Group 
A  















0.000 8.92 ± 
4.83 













0.000 9.17 ± 
5.11 













0.000 8.70 ± 
4.75 























0.000 5.44 ± 
3.93 













0.000 5.58 ± 
3.96 













0.000 5.30 ± 
4.07 

























0.237 2.12 ± 
0.45 
0.72 ± 0.20 0.012 












0.185 2.08 ± 
1.83 
0.71 ± 0.19 0.037 












0.637 2.15 ± 
0.74 

























0.060 2.62 ± 
0.62 
0.20 ± 0.10 0.000 












0.009 3.67 ± 
3.65 
0.29 ± 0.16 0.001 
















0.844 1.58 ± 
0.53 





















0.103 0.91 ± 
0.37 
0.00 0.000 0.73 ± 
0.27 
0.00 0.000 
Male 1.28 ±  
1.50 
2.09 ±  
1.04 
0.152 1.71 ±  
1.50 
0.64 ±  
0.24 
0.051 1.14 ±  
1.46 
0.00 0.000 0.85 ±  
0.40 
0.00 0.000 
Female 2.25 ±  
2.63 
2.00 ±  
1.58 
0.874 0.50 ±  
0.28 
0.60 ±  
0.40 
1.000 0.50 ±  
0.28 















Overall 7.04 ±  
0.26 
5.52 ±  
1.64 
0.000 4.32 ±  
0.31 
3.88 ±  
1.76 
0.296 3.84 ±  
0.22 
1.48 ±  
0.17 
0.000 3.56 ±  
0.29 
0.44 ±  
0.17 
0.000 
Male 6.83 ±  
0.49 
5.00 ±  
1.36 
0.003 4.25 ±  
1.96 
4.14 ±  
2.11 
0.894 3.92 ±  
1.44 
1.35 ±  
1.01 
0.000 3.17 ±  
0.49 
0.43 ±  
0.14 
0.001 
Female 7.23 ±  
0.23 
6.18 ±  
1.78 
0.024 4.38 ±  
0.31 
3.54 ±  
1.21 
0.171 3.77 ±  
0.20 
1.64  ±  
0.20 
0.000 3.92 ± 
0.31 
0.45 ±  
0.21 
0.000 




































1st week 2nd week 3rd week  4th week 
Group A  Group B p-value Group A  Group B p-value
a Group A  Group B p-value Group A  Group B p-value 


































30-39 y.o 20.67 ± 
3.98 
19.00 0.801 13.33 ± 
2.42 
5.00 0.130 11.83 ± 
3.06 
2.00 0.130 9.50 ± 
2.14 
2.00 0.130 

































































0.221 10.00 ±  
0.00 
7.00 ±  
1.00 
0.102 4.50 ±  
4.50 
0.00 ±  
0.00 
0.317 3.50 ±  
3.50 
0.00 ±  
0.00 
0.317 
30-39 y.o 14.33 ±  
1.15 
18.00 ±  
0.00 
0.203 11.33 ±  
1.23 
10.00 ±  
0.00 
0.799 8.50 ±  
0.85 
2.00 ±  
00 
0.127 6.50 ±  
0.88 
1.00 ±  
0.00 
0.130 
40-49 yo 16.50 ±  
5.01 
18.67 ±  
0.80 
0.513 11.62 ±  
5.12 
6.83 ±  
0.70 
0.038 10.25 ±  
2.96 
2.50 ±  
0.22 





50-60 y.o 15.00 ±  
4.82 
19.50 ±  
0.64 
0.018 9.78 ±  
1.45 
6.56 ±  
0.38 
0.015 7.44 ±  
3.61 
2.12 ±  
1.20 
0.000 3.56 ±  
1.27 


































20-29 y.o 6.50 ±  
2.50 
8.00 ±  
0.00 
1.000 6.50 ±  
2.50 
5.00 ±  
0.00 
1.000 3.00 ±  
1.00 
2.50 ±  
0.50 
0.683 1.50 ±  
1.50 
0.50 ±  
0.50 
0.683 
30-39 y.o 6.33 ±  
3.23 
18.00 ±  
0.00 
0.317 4.33 ±  
3.77 
10.00 ±  
0.00 
0.445 3.50 ±  
3.94 
2.00 ±  
0.00 
0.207 3.50 ±  
3.56 
1.00 ±  
0.00 
0.799 
40-49 yo 6.00 ±  
2.20 
7.83 ±  
1.72 
0.189 4.12 ±  
1.46 
4.50 ±  
0.81 
0.946 2.87 ±  
1.96 
2.67 ±  
1.21 
0.000 1.87 ±  
1.73 
1.00 ±  
0.89 
0.012 
50-60 y.o 6.33 ±  
2.45 
6.81 ±  
0.30 
0.433 3.78 ±  
1.79 
4.00 ±  
0.66 
0.953 2.89 ±  
2.08 
2.12 ±  
0.96 
0.405 1.56 ±  
0.50 
































20-29 y.o 3.00 ±  
3.00 
7.00 ±  
1.00 
0.221 6.00 ±  
1.00 
2.50 ±  
0.50 
0.121 6.50 ±  
3.50 
1.50 ±  
0.50 
0.121 6.00 ±  
6.00 
0.00 ±  
0.00 
0.317 
30-39 y.o 6.17 ± 
3.82 
6.00 ±  
0.00 
0.604 4.00 ±  
4.15 
4.00 ±  
0.00 
0.797 2.00 ±  
2.28 
2.00 ±  
0.00 
0.799 1.88 ±  
1.33 
0.00 ±  
0.00 
0.186 
40-49 yo 7.37 ±  
2.06 
6.83 ±  
0.75 
0.511 5.75 ±  
2.50 
2.83 ±  
0.75 
0.013 4.25 ± 
2.60 
1.83 ±  
0.17 
0.084 3.37 ±  
2.97 
0.00 ±  
0.00 
0.010 
50-60 y.o 6.44 ± 
3.43 
6.56 ±  
0.24 
0.506 4.67 ± 
3.74 
2.68 ±  
0.15 
0.289 2.78 ± 
0.94 
1.62 ±  
0.12 
0.952 1.44 ±  
0.65 





















0.103 0.91 ± 
0.37 
0.00 ±  
0.00 
0.000 0.73 ± 
0.27 
0.00 ±  
0.00 
0.000 
20-29 y.o 0.00 ±  
0.00 
0.00 ±  
0.00 
1.000 0.00 ±  
0.00 
0.00 ±  
0.00 
1.000 0.00 ±  
0.00 
0.00 ±  
0.00 
1.000 0.00 ±  
0.00 
0.00 ±  
0.00 
1.000 


































































Additional Problems Overall 7.04 ±  
0.26 
5.52 ±  
1.64 
0.000 4.32 ±  
0.31 
3.88 ±  
1.76 
0.296 3.84 ±  
0.22 
1.48 ±  
0.17 
0.000 3.56 ±  
0.29 
0.44 ±  
0.17 
0.000 













































































































1st week 2nd week 3rd week  4th week 
Group A  Group B p-value Group A  Group B p-value
a Group A  Group B p-value Group A  Group B p-value 

































































































































































































































































0.103 0.91 ± 
0.37 
0.00 0.000 0.73 ± 
0.27 
0.00 0.000 












































Additional Problems Overall 7.04 ±  
0.26 
5.52 ±  
1.64 
0.000 4.32 ±  
0.31 
3.88 ±  
1.76 
0.296 3.84 ±  
0.22 
1.48 ±  
0.17 
0.000 3.56 ±  
0.29 
0.44 ±  
0.17 
0.000 
Right stenting 7.15 ±  
0.22 
5.46 ±  
1.76 
0.002 4.23 ±  
0.34 
3.54 ±  
1.85 
0.272 3.92 ±  
0.21 
1.31 ±  
0.29 
0.000 4.00 ±  
0.27 
0.31 ±  
0.17 
0.000 
Left stenting 6.92 ±  
0.50 
5.58 ±  
1.56 
0.015 4.42 ±  
1,88 
4.25 ±  
1.66 
0.820 3.75 ±  
1.42 
1.67 ±  
0.18 
0.000 3.08 ±  
1.73 
0.58 ±  
0.15 
0.002 


































1st week 2nd week 3rd week  4th week 
Group A  Group B p-value Group A  
Group B 
p-value Group A  Group B p-value Group A  
Group B 
p-value 

















Normal 19.54 ±  
5.86 
21.47 ±  
2.39 
0.248 13.54 ±  
4.88 
6.07 ±  
0.60 
0.000 10.18 ±  
3.68 
3.00 ±  
1.41 
0.000 7.91 ±  
2.98 
2.13 ±  
0.26 
0.000 
Obes 21.43 ±  
4.48 
21.50 ±  
2.32 
0.960 14.93 ±  
5.09 
7.30 ±  
0.79 
0.000 12.64 ±  
4.53 
3.50 ±  
0.37 
0.000 9.71 ±  
5.89 































Normal 14.36 ±  
4.61 
19.40 ±  
2.41 
0.006 9.54 ±  
4.41 
6.87 ±  
0.46 
0.033 7.54 ±  
3.36 
2.07 ±  
0.27 
0.000 4.73 ±  
3.16 
1.40 ±  
0.27 
0.006 
Obes 16.14 ±  
3.82 
18.80 ±  
2.25 
0.052 11.71 ±  
3.67 
6.70 ±  
0.45 
0.001 9.00 ± 
3.59 
2.00 ±  
1.41 
0.000 6.00 ±  
4.49 






























Normal 6.18 ±  
2.18 
7.27 ±  
0.36 
0.167 3.82 ±  
0.60 
3.87 ±  
0.66 
0.937 2.82 ±  
2.14 
1.73 ±  
0.25 
0.262 1.64 ±  
0.62 
0.80 ±  
0.30 
0.331 
Obes 6.28 ±  
2.81 
7.30 ±  
1.64 
0.497 4.57 ±  
0.72 
4.50 ±  
2.07 
0.784 3.21 ±  
0.73 
2.90 ±  
0.28 
0.952 2.50 ±  
0.64 



































Normal 6.73 ±  
3.58 
6.53 ±  
0.29 
0.331 4.54 ±  
3.84 
3.00 ±  
0.17 
0.469 2.54 ±  
2.42 
1.73 ±  
0.12 
0.532 1.45 ±  
0.39 
0.20 ±  
0.11 
0.004 
Obes 6.14 ±  
0.79 
6.80 ±  
0.13 
0.759 5.28 ±  
2.89 
2.40 ±  
0.16 
0.010 4.00 ±  
3.16 
1.60 ±  
0.16 
0.131 3.36 ±  
0.98 





















0.103 0.91 ± 
0.37 
0.00 0.000 0.73 ± 
0.27 
0.00 0.000 
Normal 0.73 ±  
0.41 
1.33 ±  
0.40 
0.235 1.09 ±  
0.43 
0.40 ±  
0.19 
0.209 0.91 ±  
0.39 
0.00 ±  
0.00 
0.005 0.73 ±  
0.30 
0.00 ±  
0.00 
0.005 
Obes 0.71 ±  
0.43 
1.30 ±  
0.37 
0.104 0.43 ±  
0.23 
0.40 ±  
0.22 
0.941 0.21 ±  
0.11 
0.00 ±  
0.00 
0.126 0.21 ±  
0.11 













Additional Problems Overall 7.04 ±  
0.26 
5.52 ±  
1.64 
0.000 4.32 ±  
0.31 
3.88 ±  
1.76 
0.296 3.84 ±  
0.22 
1.48 ±  
0.17 
0.000 3.56 ±  
0.29 
0.44 ±  
0.17 
0.000 
Normal 6.91 ±  
0.51 
5.67 ±  
0.43 
0.004 4.09 ±  
1.58 
3.53 ±  
1.68 
0.347 3.82 ±  
1.47 
1.73 ±  
0.21 
0.000 3.54 ±  
1.63 
0.40 ±  
0.16 
0.000 
Obes 7.14 ±  
0.95 
5.30 ±  
1.64 
0.007 4.50 ±  
0.41 
4.40 ±  
1.84 
0.808 3.86 ±  
0.20 
1.10 ±  
0.28 
0.000 3.57 ±  
0.36 
0.50 ±  
0.17 
0.000 
p-valueb 0.726 0.627 
 
0.711 0.278 
 
0.861 0.089 
 
0.772 0.519 
 
 
